MYO-029 was an anti-myostatin antibody, not a short peptide. Its phase I/II trial did not show improvement in exploratory strength or function outcomes and was not powered to establish efficacy.[1]
- Publication
- 2008
- Participants
- 116 adults
- Study stage
- Phase I/II
What was studied?
The randomized trial included 116 adults with several muscular dystrophies. Its main emphasis was safety, with exploratory assessments of outcomes such as strength and function.[1]
The design matters when describing a result. An early trial can provide important information without being capable of settling a broad question about clinical effectiveness.
What did the results support?
The publication described a limited trend toward increased muscle size in a subgroup, without demonstrated improvement in the exploratory strength and function measures. Some groups experienced cutaneous hypersensitivity.[1]
A subgroup observation is not the same as a proven general benefit. A fair summary includes the outcomes that did not improve, rather than building the entire story around the most favorable observation.
Why keep an older trial in the library?
Earlier studies show how a field’s questions evolved and why later trials use more precise populations and endpoints. They also help identify claims that rely on a mechanism while overlooking direct clinical experience.
An older result does not determine every newer treatment’s outcome. Different agents and populations still need their own studies. The useful lesson is methodological: target engagement, tissue growth, and functional benefit are different links in an evidence chain.
How does this compare with later SMA research?
The later SAPPHIRE trial tested a different antibody strategy in a different neuromuscular-disease population. Comparing the study questions can be useful; treating the two results as directly interchangeable would not be.
Use the trial-reading guide to record the intervention, population, endpoint, and study purpose before drawing a cross-study conclusion. That keeps both early uncertainty and later progress visible.
Questions, answered.
Was MYO-029 a peptide supplement?
No. It was a neutralizing antibody studied as a clinical intervention.
Does this trial prove every myostatin inhibitor will fail?
No. It concerns one agent and design. It does show why a shared biological target cannot guarantee a clinical result.
Sources & further reading
Primary research and official records used for this page. Study results apply to the populations and interventions described.
- A phase I/II trial of MYO-029 in adult subjects with muscular dystrophyWagner et al. · Annals of Neurology · 2008 · Randomized trial